Bio Speciality Assay Lab Profile
Key Indicators
- Authorised Capital ₹ 0.60 M
as on 31-07-2024
- Paid Up Capital ₹ 0.50 M
as on 31-07-2024
- Company Age 37 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -12.70%
(FY 2023)
- Profit 45.19%
(FY 2023)
- Ebitda 54.78%
(FY 2023)
- Net Worth -19.35%
(FY 2023)
- Total Assets -15.27%
(FY 2023)
About Bio Speciality Assay Lab
The Corporate was formerly known as Bio Speciality Assay Lab Limited. The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.60 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Birupaksha Sarkar, Narayani Sarkar, and Vinay Kapadia serve as directors at the Company.
- CIN/LLPIN
U24232WB1987PTC042644
- Company No.
042644
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Jul 1987
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Bio Speciality Assay Lab?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Birupaksha Sarkar  | Director | 01-Jan-2007 | Current |
| Narayani Sarkar | Director | 30-Sep-2009 | Current |
| Vinay Kapadia | Director | 06-Jul-1987 | Current |
Financial Performance of Bio Speciality Assay Lab.
Bio Speciality Assay Lab Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 12.7% decrease. The company also saw a substantial improvement in profitability, with a 45.19% increase in profit. The company's net worth observed a substantial decline by a decrease of 19.35%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bio Speciality Assay Lab?
In 2023, Bio Speciality Assay Lab had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
_LTD.webp)
Reltech Biomedical Systems LtdActive 37 years 2 monthsBirupaksha Sarkar, Narayani Sarkar and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Bio Speciality Assay Lab?
Unlock and access historical data on people associated with Bio Speciality Assay Lab, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bio Speciality Assay Lab, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bio Speciality Assay Lab's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
